STOCK TITAN

Enanta Pharmaceuticals, Inc - ENTA STOCK NEWS

Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.

Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.

In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.

Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.

Rhea-AI Summary
Enanta Pharmaceuticals, Inc. announced participation in a fireside chat at Leerink Partners Global Biopharma Conference. The event will feature the company's President and CEO, Jay R. Luly, and Chief Product Strategy Officer, Tara L. Kieffer. The webcast will be available on Enanta's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. reported financial results for its fiscal first quarter ended December 31, 2023, with total revenue of $18.0 million. The company aims to announce topline data for RSVPEDs and EDP-323 challenge study in Q3 2024. They also expanded into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria, targeting a development candidate selection in 2024. Cash and Marketable Securities totaled $337.2 million at December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be live webcast and accessible on the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) plans to report its fiscal first-quarter financial results on February 7, 2024, after the U.S. market closes. The company will host a conference call to discuss the results and provide an update on its business and research and development pipeline. A live webcast of the event will be accessible on Enanta's website. Participants can also join by phone and a replay of the webcast will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
-
Rhea-AI Summary
Enanta Pharmaceuticals, a clinical-stage biotechnology company (NASDAQ:ENTA), announced expansion into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria (CSU). They also expect topline data from at least one Phase 2 study of Zelicapavir (EDP-938), an N-Protein Inhibitor in development to treat Respiratory Syncytial Virus (RSV), in 3Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.8%
Tags
none
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
conferences
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (ENTA) announced that its President and CEO, Dr. Jay R. Luly, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023. The event will be live webcasted and accessible through the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
conferences
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV). The company expects to report data in Q3 2024. Enanta also streamlined business and significantly lowered 2024 R&D and G&A spending guidance to support ongoing operations. Cash and Marketable Securities totaled $370 million at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to Report Q4 and Full Year 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences

FAQ

What is the current stock price of Enanta Pharmaceuticals (ENTA)?

The current stock price of Enanta Pharmaceuticals (ENTA) is $11.19 as of October 3, 2024.

What is the market cap of Enanta Pharmaceuticals (ENTA)?

The market cap of Enanta Pharmaceuticals (ENTA) is approximately 238.6M.

What is the focus of Enanta Pharmaceuticals?

Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections and liver diseases.

Where is Enanta Pharmaceuticals located?

Enanta Pharmaceuticals is located in Watertown, Massachusetts.

What are some of the diseases Enanta targets?

Enanta targets hepatitis C, hepatitis B, nonalcoholic steatohepatitis (NASH), and respiratory syncytial virus (RSV).

What is paritaprevir?

Paritaprevir is a lead protease inhibitor developed by Enanta and is part of AbbVie's approved HCV treatment regimen.

Does Enanta collaborate with other companies?

Yes, Enanta collaborates with AbbVie to market its protease inhibitors and is working on developing other promising drug candidates.

What is Enanta’s approach to drug discovery?

Enanta uses a chemistry-driven approach and robust drug discovery capabilities to develop novel small molecule drugs.

What is NASH?

Non-alcoholic steatohepatitis (NASH) is a liver disease characterized by inflammation and damage due to fat buildup.

What are DAAs?

Direct-acting antivirals (DAAs) are a class of drugs that directly target viral functions to combat infections, such as those caused by the hepatitis C virus.

What is an HTA inhibitor?

A host-targeted antiviral (HTA) inhibitor is designed to target host cell functions that viruses exploit to reproduce, providing a novel approach to antiviral therapy.

What makes Enanta significant in the biotech industry?

Enanta's commitment to innovation, strategic collaborations, and focus on serious diseases like hepatitis C and NASH positions it as a significant player in the biotech industry.

Enanta Pharmaceuticals, Inc

Nasdaq:ENTA

ENTA Rankings

ENTA Stock Data

238.58M
21.19M
6.09%
105.69%
13.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN